Dr. Nuyten will oversee Arcus’s clinical development organization that includes nearly 200 employees and six clinical-stage programs targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1HAYWARD, Calif. (BUSINESS WIRE) Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceu.
Stock Market | Daily Herald dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
Nektar Appoints Dimitry S A Nuyten, M D , Ph D , as Senior Vice President and Chief Medical Officer apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.